

**Supplementary Table 1. Clinical trials of COVID-19 vaccine in people living with HIV.**

NCT number	Title	Status	Study type	Phase	Study design	Number enrolled	Vaccination type	Region
NCT05075044	Immunogenicity and safety of an inactivated COVID-19 vaccine in people aged $\geq 18$ years with HIV infected	Recruiting	Interventional	Phase 4	Open label, single group	400	Inactivated	China
NCT05075070	Immunogenicity and safety of an inactivated COVID-19 vaccine in people with HIV infected	Recruiting	Interventional	Phase 4	Open label, single group	400	Inactivated	China
NCT05105295	Immunogenicity and a safety of a third dose and immune persistence of BBIBP-Corv vaccine in people with HIV infected	Not yet recruiting	Interventional	Phase 4	Open label, single group	400	Inactivated	China
NCT05085145	The efficacy of COVID-19 vaccine in patients with HIV infection, a prospective and multicenter clinical trial	Recruiting	Interventional	Phase 4	Open label, single group	200	Unlimited	China
NCT04894448	Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)	Recruiting	Observational	NA	Prospective	500	Unlimited	China
NCT05043129	Safety and immune response of COVID-19 vaccination in patients with HIV infection	Recruiting	Observational	NA	Prospective	200	Unlimited	China
NCT05435027	A phase 1 SARS-CoV-2 vaccine study to assess the safety and tolerability of GRT-R912, GRT-R914, and GRT-R918 administered as prime and/or boost in healthy adult participants and people living with HIV	Recruiting	Interventional	Phase 1	Open label, parallel assignment	340	mRNA	South Africa

NCT04444674	An adaptive phase I/II randomized placebo-controlled trial to determine safety, immunogenicity and efficacy of non-replicating ChAdOx1 SARS-CoV-2 vaccine in South African adults living without HIV; and safety and immunogenicity in adults living with HIV	Active, not recruiting	Interventional	Phase 1,2	RCT	2130	ChAdOx1 nCoV-19	South Africa
NCT05112848	A phase 2, randomized, observer-blinded study to evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with matrix-M™ adjuvant in people living with HIV	Active, not recruiting	Interventional	Phase 2	RCT	360	NVX-CoV2373	South Africa
NCT04533399	A phase 2A/B, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, immunogenicity, and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with matrix-M1™ adjuvant in South African adult subjects living without HIV; and safety and immunogenicity in adults living with HIV	Completed	Interventional	Phase 2	RCT	4422	NVX-CoV2373	South Africa
NCT05168813	Multi-center, randomized, efficacy study of COVID-19 mRNA vaccine in regions with SARS-CoV-2 variants of concern	Recruiting	Interventional	Phase 2,3	RCT	15600	mRNA-1273	Eastern and Southern Africa
NCT04779996	Antibodies production after COVID-19 vaccination among patients with medical history of cancer and anti-CD-20 treatment	Recruiting	Observational	NA	Cross-sectional	250	Unlimited	Puerto Rico

NCT05067400	SARS-CoV-2 (COVID-19) antibody prevalence in an adult London HIV cohort	Recruiting	Observational	NA	Cross-sectional	1500	Unlimited	United Kingdom
NCT04844489	Study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19 in immunocompromised people	Recruiting	Interventional	NA	Open label, single group	485	Unlimited	France
NCT04754698	Immunogenicity and safety of the CoronaVac vaccine in patients with autoimmune rheumatic diseases and people living with HIV/AIDS	Recruiting	Interventional	Phase 4	Open label, parallel assignment	2067	CoronaVac	Brazil
NCT05104359	Should COVID-19 quantitative antibody titers be implemented to guide COVID-19 booster vaccinations regardless of HIV status, immunosuppression, or age?	Completed	Observational	NA	Cohort, retrospective	825	Unlimited	United States
NCT05005156	A randomized, double-blind, placebo-controlled, phase IIb clinical Trial to evaluate the efficacy, safety and immunogenicity of one or two doses of recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older, living with HIV, on stable treatment, and virologically suppressed for at least 6 months.	Recruiting	Interventional	Phase 2	RCT	876	Ad5-nCoV	Argentina

RCT: Randomized controlled trial; NA: Not applicable; AIDS: Acquired immunodeficiency syndrome; NA: Not applicable; RCT: Randomized controlled trial;

COVID-19: Coronavirus disease 2019; HIV: Human immunodeficiency virus; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.